Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with Erdafitinib in Combination with Cetrelimab, a PD-1 Inhibitor
- EMEA Innovative Medicine
- Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with Erdafitinib in Combination with Cetrelimab, a PD-1 Inhibitor
Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with Erdafitinib in Combination with Cetrelimab, a PD-1 Inhibitor
- X (Twitter)
Copy link